Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.